CXCL5 also has a higher expression in ccRCC [31], which role in metastasis, tumor development, and angiogenesis [32], has led to its designation as a key biomarker and supplementary antiangiogenic treatment target [33]. The gene discussed is CXCL5; the disease is nonpapillary renal cell carcinoma.